Cibus, Inc. (CBUS) 10-K Summary: Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Cibus, Inc. is an agricultural biotechnology company utilizing proprietary gene editing technology (RTDS) to develop plant traits for major crops. The reporting period covers the fiscal year ended December 31, 2025. The Company is a "smaller reporting company" and a holding company whose primary asset is its interest in Cibus Global, LLC. In 2025, Cibus executed a strategic streamlining of operations, reducing its workforce and consolidating facilities to focus capital on its priority Rice herbicide tolerance (HT) traits and sustainable ingredients programs.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $3.6 million | $4.3 million |
| Net Loss | $(132.2) million | $(282.7) million |
| Net Loss Attributable to Stockholders | $(127.1) million | $(251.4) million |
| Operating Cash Flow | $(50.6) million | $(58.0) million |
| Cash and Cash Equivalents (Year-End) | $9.9 million | $14.4 million |
| Current Liabilities | $16.9 million | $19.9 million |
| Goodwill Impairment | $21.0 million | $181.4 million |
| Long-Lived Asset Impairment | $9.1 million | $0 |
| Royalty Liability Interest Expense | $35.5 million | $34.2 million |
Note: The filing does not provide specific gross or net margin percentages due to the lack of significant commercial royalty revenue.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 53% year-over-year, primarily driven by a significant reduction in goodwill impairment charges ($21.0 million in 2025 vs. $181.4 million in 2024) and cost reduction initiatives.
- Revenue Decline: Revenue decreased by 15% to $3.6 million, attributed to lower amounts earned from collaboration agreements related to contract research.
- Expense Reductions: Research and Development (R&D) expenses decreased by 12% ($44.2 million) and Selling, General, and Administrative (SG&A) expenses decreased by 13% ($26.9 million) due to workforce reductions and facility consolidations.
- Asset Impairments: The Company recorded a $9.1 million impairment of long-lived assets related to the wind-down of its Roseville, Minnesota facility, a new charge not present in 2024.
- Capital Raising: The Company raised approximately $66.2 million in net proceeds through three equity offerings in 2025 (January, June) and early 2026 (January).
Guidance, Outlook, and Risks
Going Concern Uncertainty: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements. As of December 31, 2025, cash on hand ($9.9 million) was insufficient to fund operations for 12 months. However, following a $19.8 million offering in January 2026 and cost-saving measures, management expects cash to be sufficient into late Q3 2026.
Strategic Focus: The Company is streamlining operations to lower annual net cash usage to approximately $30.0 million or less in 2026. Priority is placed on commercializing Rice HT traits (targeting 2027-2028 launch) and sustainable ingredients (biofragrances).
Regulatory Outlook: Significant progress was made in the EU, where trilogue negotiations on New Genomic Techniques (NGT) concluded in December 2025, potentially allowing non-GMO regulation for certain gene-edited plants by 2028. The Company also secured positive regulatory determinations in the US (USDA-APHIS) and Ecuador.
Risks:
- Liquidity: Continued need for additional financing to sustain operations.
- Commercialization: No revenue-generating commercial contracts for traits exist yet; revenue depends on successful licensing to seed companies.
- Royalty Liability: A significant non-cash interest expense ($35.5 million) accrues on a royalty liability to related parties, which will require cash payments once revenue thresholds are met.
- Regulatory: While improving, regulatory frameworks for gene editing vary globally and could change adversely.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $19.8 million raised in January 2026 combined with year-end cash to fund operations through late Q3 2026 as projected.
- Royalty Liability Trigger: Monitor when aggregate subject revenues exceed $50.0 million in a consecutive 12-month period, which would trigger cash payments on the accrued $0.6 million unpaid royalty balance plus future accruals.
- Rice Trait Progress: Track the timeline for the 2027-2028 commercial launch of Rice HT traits in Latin America and the US, which is the primary near-term revenue driver.
- Goodwill Valuation: Assess the remaining $232.5 million goodwill balance against future stock price performance and regulatory developments, as further impairments are possible.
- Cost Reduction Execution: Confirm the realization of the targeted $30.0 million annual net cash usage in 2026 following the workforce reductions and facility closures.